0.6 mg to improve GI tolerability for 1 week
While some patients experience nausea with Victoza®, for most it lessens over time1
How to write a prescription for Victoza® in the e-prescribing system
Change the course of treatment with Victoza® for your patients with T2D and established CVD
Buse (LEAD-6)1: A 26-week, open-label, active-comparator, parallel-group, multinational study to compare the safety and efficacy of Victoza® with exenatide in patients with type 2 diabetes not adequately controlled on metformin or sulfonylurea or both. Patients (N=464) were stratified by previous oral antidiabetic therapy and randomized to receive once-daily Victoza® (1.8 mg/day, n=233) or exenatide (10 µg, twice a day, n=231) both in combination with metformin and/or sulfonylurea. The primary outcome was change in A1C.1
- Buse JB, Rosenstock J, Sesti G, et al; for the LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39-47.